Palo Alto, United States
ENDPOINT HEALTH, founded in 2018, is gaining traction in the Health Care industry by focusing on Precision immunology therapies. Based in the United States, this company is carving out a niche with its innovative approach to treating immune-mediated chronic and acute diseases.
By leveraging a proprietary artificial intelligence (AI) platform, ENDPOINT HEALTH combines companion diagnostics with therapeutics to create precision therapies tailored to the unique biology and disease of each patient. With its vision of personalized treatment for all, the company addresses significant unmet needs and presents a valuable opportunity within a rapidly evolving sector.
The company's promising trajectory was reinforced by a substantial $52.00M Series A investment on 02 June 2022. This funding round saw participation from a notable consortium of investors including The Venture Collective (TVC), Wireframe Ventures, Boom Capital Ventures, and others. This diverse pool of backers underlines confidence in ENDPOINT HEALTH's strategic direction and potential for impactful growth.
